Merck Lifts Guidance, Sales Driven by Diabetes Treatment

NEW YORK (TheStreet) -- Merck (MRK) raised the lower end of its full-year guidance as its topped analysts' estimates for the third quarter.

The company raised the low end of its previous full-year earnings estimate range and now expects $3.72 to $3.76 a share. Merck said it expects to see revenue growth for the year in the mid-single-digits range.

The company posted third-quarter earnings excluding items of $2.91 billion, or 94 cents a share, compared to $2.65 billion, or 85 cents a share, in the year-ago period. Revenue was up 8% to $12 billion.

Analysts were expecting earnings per share of 91 cents on revenue of $11.91 billion.

Revenue was driven by the success of the company's combined diabetes treatment Januvia/Janument. The company reported worldwide sales grew 41% to $1.2 billion in the third quarter driven by strong growth in all regions.

Follow TheStreet on Twitter and become a fan on Facebook.

Sales of asthma drug Singulair grew 10% from the third quarter of 2010 to $1.3 billion.

--Written by Carlton Wilkinson

More from Stocks

Stocks Finish Higher After Release of Fed Minutes

Stocks Finish Higher After Release of Fed Minutes

Has Wall Street Completely Lost Its Mind on General Electric?

Has Wall Street Completely Lost Its Mind on General Electric?

Did Trump Just Torpedo the Stock Market Again?

Did Trump Just Torpedo the Stock Market Again?

10 Questions for PayPal Ahead of Its Big Investor Day

10 Questions for PayPal Ahead of Its Big Investor Day

Lowe's Taps Home Depot Veteran As New CEO

Lowe's Taps Home Depot Veteran As New CEO